Brand Name | Status | Last Update |
---|---|---|
dexamethasone sodium phosphate 0.1% / finasteride 0.1% / minoxidil 5% | unapproved drug other | 2019-05-08 |
dexamethasone sodium phosphate 0.1% / finasteride 0.1% / minoxidil 5% / tretinoin 0.025% | unapproved drug other | 2019-05-08 |
entadfi | New Drug Application | 2023-01-12 |
finasteride | ANDA | 2025-02-10 |
finasteride 0.1% / minoxidil 5% | unapproved drug other | 2019-05-08 |
finasteride 0.1% / minoxidil 7% | unapproved drug other | 2019-04-24 |
finasteride 0.1% / minoxidil 7% / tretinoin 0.025% | unapproved drug other | 2019-05-10 |
johnson foam pro | C200263 | 2024-11-21 |
nr-11 | Export only | 2017-06-21 |
propecia | New Drug Application | 2024-10-14 |
Code | Description |
---|---|
S0138 | Finasteride, 5 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Drug common name | Finasteride |
INN | finasteride |
Description | Finasteride is an aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia. It has a role as an androgen antagonist, an EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor and an antihyperplasia drug. It is an aza-steroid, a 3-oxo steroid and a delta-lactam. It derives from a hydride of a 5alpha-androstane. |
Classification | Small molecule |
Drug class | steroids (androgens, anabolics); testosterone reductase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |
PDB | — |
CAS-ID | 98319-26-7 |
RxCUI | — |
ChEMBL ID | CHEMBL710 |
ChEBI ID | 5062 |
PubChem CID | 57363 |
DrugBank | DB01216 |
UNII ID | 57GNO57U7G (ChemIDplus, GSRS) |